World Health Organization Raises Concern Over Severe Lack of Weight-Loss Jabs

Fewer than a tenth of patients who could benefit from weight-loss injections including Wegovy can access them, caution the World Health Organization as it issues its initial advice on the therapies.

Given over a billion individuals worldwide now obese, it is advocating for more widespread and fairer access to this class of drugs.

Based on projections, over two billion could be obese by 2030 without intervention.

"Our latest guidance acknowledges that obesity is a chronic disease that can be treated with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the jabs that can assist patients in reducing considerable body mass, says the organization.

Weight-Loss Drug Shortage

Even under the current most favorable case, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of the global need, according to the health organization.

The advice encourages countries and companies to expand access, by approaches like voluntary licensing.

A patent on semaglutide – the core component of a leading brand – is scheduled to end in multiple nations in 2026.

The Way Obesity Injections Function

The injections imitate a natural hormone to slow digestion, suppress the appetite and boost feelings of fullness so users reduce food intake.

Individuals usually start to lose weight within a few weeks of beginning the regular doses.

Studies points to people may regain a significant portion within a year of discontinuing the medication, because their typical hunger come back.

Being overweight or obese raises your likelihood for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies.

Excess weight affects people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.